Reprints
PubMed
CAVEAT LECTOR
PROSTAGLANDINS AND CANCER
The University of Texas M. D. Anderson Cancer Center, Science Park-Research Division, Smithville, TX 78957
Received 9/3/97 Accepted 9/23/97
8. REFERENCES
1.Jaffe, B. M.: Prostaglandins and cancer: An update. Prostaglandins 6, 453-461 (1974)
2.Karmali, R. A.: Prostaglandins and cancer. Review. Prostaglandins 5, 11-28 (1980)
3. Marnett, L. J.: Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52, 5575-5589 (1992)
4.Levy, G. N.: Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs and colon cancer. FASEB J 11, 234-247 (1997)
5.Marnett, L. J.: Prostaglandin synthase-mediated metabolism of carcinogens and a potential role for peroxyradicals as positive interediates. Environ Health Perspec 88, 5-12 (1990)
6. Ziboh, V A : Arachidonic acid metabolism in the skin. In: Arachidonic Acid Metabolism and Tumor Promotion. Eds: Fischer S M, Slaga T J, Martinus Nijhoff Publ., Boston, 5-20 (1985)
7. Galey, C. I., V. A. Ziboh, C. L. Marcelo & J. J. Voorhees: Modulation of phospholipid metabolism in murine keratinocytes by tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate. J Invest Dermatol 85, 319-323 (1985)
8. Ford-Hutchinson, A. W.: Arachidonic acid metabolism: enzymatic pathways. In: Eicosanoids and the Skin, Ed: Ruzick T, CRC Press, Boca Raton, 3-22 (1990)
9. Ogino, N., T. Miyamoto, S. Yamamoto & O. Hayaishi: Prostaglandin endoperoxide E isomerase from bovine vesicular microsomes, a glutathione-requiring enzyme. J Biol Chem 253, 890-895 (1978)
10. Nugteren, D. H. & E. Hazelhof: Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 326, 448-461 (1973)
11. Pace-Asciak, C. R.: Oxidative biotransformations of arachidonic acid. Prostaglandins 13, 811-817 (1977)
12.Funk, C. D.: The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim Biophys Acta 1304, 65-84 (1994)
13.Murphy, R. C. & D. D. Stene: Oxidative metabolism of leukotriene E4 by rat hepatocytes. Ann NY Acad Sci 524, 35-42 (1988)
14.Lehman, W. D.: Regio- and stereo-chemistry of the dioxygenation reaction catalyzed by (s)-type lipoxygenases or by the cyclooxygenase activity of prostaglandin H synthases. Free Rad Biol Med 16, 241-253 (1994)
15. Capdevilla, J., L. J. Marnett, N. Chacos, R. A. Prough & R. W. Estabrook: Cytochrome P-450-dependent oxygenation of arachidonic acid to hydroxyeicosatetraenoic acids. Proc Natl Acad Sci USA 79, 767-770 (1982)
16.Reiners, J. J., A. R. Cantu & A. Schöller: Phorbol-ester mediated suppression of cytochrome P450 cyp1a-1 induction in murine skin: involvement of protein kinase C. Biochem Biophys Res Commun 186, 970-976 (1992)
17.Schwartzman, M. L.: Modification of arachidonic acid metabolism via the cytochrome P450-related monooxygenase system. In: Adv. Prostaglandin, Thromboxane and Leukotriene Research., Eds. Samuelsson B, Ramwell P, Paoletti R. Raven Press Ltd., NY, 241-249 (1990)
18.Nelson, R. L., J. C. Tanure, G. Andrianopoulos, G. Souza & W. E. M. Lands: A comparison of dietary fish oil and corn oil in experimental colorectal carcinogenesis. Nutr Cancer 11, 215-220 (1988)
19.O'Connor, T. P., B. D. Roebuck, F. Peterson & T. C. Campbell: Effect of dietary intake of fish oil and fish protein on the development of L-azaserine-induced preneoplastic lesions in the rat pancreas. J Natl Cancer Inst 75, 959-962 (1985)
20. Belury, M. A., K. E. Patrick, M. Locniskar & S. M. Fischer: Eicosapentaenoic and arachidonic acid: Comparison of metabolism and activity in murine epidermal cells. Lipids 24, 423-429 (1989)
21. Bowser, P. A., D. H. Nugeren, R. J. White, U. M. T. Hontsmuller & C. Prottey: Identification, isolation and characterization of epidermal lipids containing linoleic acid. Biochem Biophys Acta 834, 419-428 (1985)
22.Miller, C. C. & V. A. Ziboh: Induction of epidermal hyperproliferation by topical n-3 polyunsaturated fatty acids on guinea pig skin linked to decreased levels of 13-hydroxyoctadecadienoic acid (13-HODE). J Invest Dermatol 94, 353-358 (1990)
23.Roberts, L. J. & J. D. Morrow. The generation and actions of isoprospanes. Biochem Biophys Acta 1345, 121-135 (1997)
24.Smith, W. L.: Prostanoid biosynthesis and mechanisms of action. Am J Physiol 263, F181-F191 (1992)
25.Bereziat, G., J. Etienne, M. Kokkinidis, J. L. Oliviera & P. Pernas: New trends in mammalian non-pancreatic phospholipase A2 research. J Lipid Mediators 2, 159-172 (1990)
26.Nakano, T., O. Ohara, H. Teraoka & H. Arita: Group II phospholipase A2 mRNA synthesis is stimulated by two distinct mechanisms in rat vascular smooth muscle cells. FEBS Lett 261, 171-174 (1990)
27.Paglin, S., R. Roy & P. Polgar: Characterization of hormonally regulated and particulate-associated phospholipase A2 from bovine endothelial cells. J Biol Chem 268, 11697-11702 (1993)
28.Lin, L.-L., M. Wartmann, A. Y. Lin, J. L. Knopf, A. Seth & R. J. Davis: cPLA2 is phosphorylated and activated by MAP kinase. Cell 72, 269-278 (1993)
29.Nemenoff, R. A., S. Winitz, N-X. Qian, V. Van Patten, G. L. Johnson & L. E. Heasley: Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 micro-tubule associated protein kinase and protein kinase C. J Biol Chem 268, 1960-1964 (1993)
30.Wijkander, J. & R. Sundler: An 100-kDa arachidonate-mobilizing phospholipase A2 in mouse spleen and the macrophage cell line J774. Fed Eur Biochem Soc 311, 299 (1992)
31. Davidson, F. F. & E. A. Dennis: Biological relevance of lipocortins and related proteins as inhibitors of phospholipase A2. Biochem Pharmacol 38, 3645-3651 (1989)
32.Schwartz, J. A., A. Viaje, T. J. Slaga, S. H. Yuspa, H. Hennings & U. Lichti: Fluocinolone acetonide: A potent inhibitor of mouse skin tumor promotion and epidermal DNA synthesis. Chem Biol Interact 17, 331-347 (1977)
33. Clark, M. A., T. M. Conway, R. G. L. Schorr & S. T. Crooke: Identification and isolation of a mammalian protein which is antigenically and functionally related to the phospholipase A2 stimulatory peptide melittin. J Biol Chem 262, 4402-4406 (1987)
34. Clark, M. A., L. E. Özgür, T. M. Conway, J. Dispoto, S. T. Crooke & J. S. Bomalaski: Cloning of a phospholipase A2 activating protein. Proc Natl Acad Sci USA 88, 5418-5422 (1991)
35.Sigal, E.: The molecular biology of mammalian arachidonic acid metabolism. Am J Physiol 260, L13-L28(1991)
36.Simonson, M. S., J. A. Wolfe & M. J. Dunn: Regulation of prostaglandin synthesis by differential expression of the gene encoding prostaglandin endoperoxide synthase. In: Advances in Prostaglandin, Thromboxane and Leukotiene Research, Eds: Sammuelsson B, Ramwell P, Paoletti R. Raven Press, NY, 21-69, (1990)
37.Smith, W. L., D. L. DeWitt, S. A. Kraemer, M. J. Andrews, T. Hla, T. Maciag & T. Shimokawa: Structure-function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases. In: Advances in Prostaglandin, Thromboxane and Leukotiene Research. Eds: Samuelsson, B., Ramwell P, Paoletti R. Raven Press, N Y, 20-24 (1990)
38.Maldve, R. & S. M. Fischer: Multifactor regulation of prostaglandin H synthase-2 in murine keratinocytes. Mol Carcinogenesis 17, 207-216 (1996)
39.Wu, K. K., H. Hatazkis, S. S. Lo, D. C. Seong & S. K. Sanduja: Stimulation of de novo synthesis of prostaglandin G/H synthase in human endothelial cells by phorbol ester. J Biol Chem 263, 19043-19047 (1988)
40. Gschwendt, M., G. Fürstenberger, W. Kittstein, E. Besemfelder, W. E. Hull, H. Hagedorn, H. J. Operkuch & F. Marks: Generation of the arachidonic acid metabolite 8-HETE by extracts of mouse skin treated with phorbol ester in vivo: Identification by 1H-n.m.r. and GC-MS spectroscopy. Carcinogenesis 7, 449-455 (1986)
41. Fischer, S. M., J. K. Baldwin, D. W. Jasheway, K. E. Patrick & G. S. Cameron: Phorbol ester induction of the 8-lipoxygenase in inbred SENCAR (SSIN) but not C57B1/6J mice correlated with hyperplasia, edema and oxidant generation but not ornithine decarboxylase induction. Cancer Res 48, 658-664 (1988)
42. Fürstenberger, G. & F. Marks: The role of eicosanoids in normal hyperplastic and neoplastic growth in mouse skin. In: Eicosanoids and the Skin. Ed: Ruzicka, T. CRC Press, Boca Raton, 107-124 (1990)
43. Stephan, M., W. D. Lehmann, T. Jacobi & G. Fürstenberger: Determination of tissue levels of monohydroxylated fatty acids (HODEs and HETEs) in normal, hyperplastic and neoplastic mouse epidermis by gas chromatography - mass spectrometry and stable isotope dilution. J Cancer Res Clin Oncol 117, S32 (1991)
44.Narumiya, S.: Prostanoid receptors. In: Cellular generation, transport, and effect of eicosanoids. Eds: Goetzl E J, Lewis RA, Rola-Pleszczymski M, Ann NY Acad Sci 744, 126-138 (1994)
45.Goetzl, E. J., J. Yang, M. Xia, L. Zeng, S. W. So & S. An: Diverse mechanisms of specificity of human receptors for eicosanoids. In: Cellular generation, transport, and effects of eicosanoids. Eds: Goetzl E J, Lewis RA, Rola-Pleszczynski M, Ann NY Acad Sci 744, 146-154 (1994)
46.Negishi, M., Y. Sugimoto & A. Ichikawa. Molecular mechanisms of diverse actions of prostanoid receptors. Biochim Biophys Acta 1259, 109-120 (1995)
47.Halushka, P. V., D. E. Mais, P. R. Mayeux & T. A., Morinelli: Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharm Tox 29, 213-239 (1989)
48.Negishi, M., Y. Sugimoto, A. Irie, S. Narumiya & A. Ichikawa: Two isoforms of prostaglandin E receptor EP3 subtype. J Biol Chem 268, 9517-9521 (1993)
49.Namba, T., Y. Sugimoto, M. Negishi, A. Irie, F. Ushikuba, A. Kakizuka & S. Ito: Ichikawa, A., Narumiya, S.: Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 365, 166-170 (1993)
50.Sugimoto, Y., M. Negishi, Y. Hayashi, T. Namba, A. Honda, A. Watabe, M. Hirata, S. Narumiya & A. Ichikawa: Two isoforms of the EP3 receptor with different carboxy-terminal domains. J Biol Chem 268, 2712-2718 (1993)
51.Honda, A., Y. Sugimoto, T. Namba, A. Watabe, Irie, M. Negishi, S. Narumiya & A. Ichikawa: Cloning and expression of a cDNA for mouse prostaglandin-E receptor EP2 subtype. J Biol Chem 268, 7759-7762 (1993)
52. Breyer, R. M., R. B. Emeson & M. D. Breyer: Alternative splicing generates multiple isoforms of the prostaglandin E2 EP3 receptors. In: Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury. Eds: Honn K V, Marnett L J, Nigam S, Kluwer, Academic Press, Boston, (in press)
53.Muller, A., L. Michel, N. Basset-Sequin, G. Modat, G. Dubertret & C. Bonne: Characterization of specific leukotriene C4 binding sites on cultured human keratinocytes. Br J Dermatol 119, 275-280 (1988)
54.Gross, E., T. Ruzicka, C. Mauch & T. Krieg: Evidence for LTB4/12-HETE binding sites in a human epidermal cell line. Prostaglandins 36, 49-58 (1988)
55.Kemeny, L., B. Przybilla, E. Gross, P. Arenberger & T. Ruzicka: Inhibition of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] binding to epidermal cells by ultraviolet B. J Invest Dermatol 97, 1028-1031 (1991)
56. Cameron, G. S., B. K. Stadig & S. M. Fischer: Prostaglandin E2 receptors and the effects of phorbol ester on prostaglandin E2 binding in cultured mouse keratinocytes. J Invest Dermatol 98, 640, 1992.
57.Krey, G., O. Braissant, F. L. Horset, E. Kalkhoven, M. Perroud, M. G. Parker & W. Wakli: Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands for peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Molec Endocrin 11, 779-791 (1997)
58.Kliewer, S. A., S. S. Sundseth, S. A. Jones, P. J. Brown, G. B. Wisely, C. S. Koble, P. Devchand, W. Wahli, T. M. Willson, J. M. Lenherd & J. M. Lehmann: Fatty acids and eiconsanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma.Proc Natl Acad Sci USA 94, 4318-4323 (1997)
59.Forman, B. M., J. Chen & R. M. Evans: Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxidome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 94, 4312-4317 (1997)
60. Slaga , T. J., S. M. Fischer, K. Nelson & G. L. Gleason: Studies on the mechanism of skin tumor promotion: Evidence for several stages in promotion. Proc Natl Acad Sci USA 77, 3659-3663 (1980)
61. Slaga, T. J., A. J. P. Klein-Szanto, S. M. Fischer, C. E. Weeks, K. Nelson & S. Major: Studies on the mechanism of action of anti-tumor promoting agents: Their specificity in two-stage promotion. Proc Natl Acad Sci USA 77, 2251-2254 (1980)
62. Cameron, G. S., J. K. Baldwin, R. C. Klann, K. E. Patrick & S. M. Fischer: The tumor promoting activity of ethyl phenylpropriolate (EPP) under conditions of sustained hyperplasia. Cancer Res 51, 5642-5648 (1991)
63.Janoff, A., A. Klassen & W. Troll: Local vascular changes induced by the cocarcinogen phorbol myristate acetate. Cancer Res 30, 2568-2571 (1970)
64.Slaga, T. J., S. M. Fischer, C. E. Weeks & A. J. P. Klein-Szanto: Inhibition of tumor promotion by anti-inflammatory agents: An approach to the biochemical mechanism of promotion. In : Carcinogenesis: Mechanisms of Tumor Promotion and Cocarcinogenesis. Eds: Slaga T J, Sivak A, Boutwell R K. Raven Press, NY 173-195 (1978)
65. Fischer, S. M., K. E. Patrick, B. Patamali & T. J. Slaga: Effects of antihistamines on phorbol ester tumor promotion and vascular permeability changes. Carcinogenesis 11, 991-996 (1990)
66. Lee, W., S. M. Fischer, A. P. Butler & M. F. Locniskar: Modulation of IL-1alpha mRNA expression in mouse epidermis by tumor promoters and antagonists. Molec Carcinogenesis 7, 26-35 (1993)
67. Fürstenberger, G., M. Rogers, R. Schnapke, G. Bauer, P. Hofler & F. Marks: Stimulatory role of transforming growth factors in multistage skin carcinogenesis: Possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin. Int J Cancer 43, 915-921 (1989)
68.Fischer, S. M., G. L. Gleason, L. G. Hardin, J. S. Bohrman & T. J. Slaga: Prostaglandin molulation of phorbol ester skin tumor promotion. Carcinogenesis 1, 245-248 (1980)
69.Lupulescu, A.: Enhancement of carcinogenesis by prostaglandins. Nature 272, 634-636 (1978)
70.Lupulescu, A.: Hormonal regulation of epidermal tumor development. J Invest Dermatol 77, 186-195 (1981)
71. Verma, A. K., H. M. Rice & R. K. Boutwell: Prostaglandins and skin tumor promotion: Inhibition of tumor-promoter induced ornithine decarboxylase activity in epidermis by inhibitors of prostaglandin synthesis. Biochem Biophys Res Commun 79, 1160-1166 (1977)
72.Marks, F., D. L. Berry, S. Bertsch, G. Fürstenberger & H. Richter: On the relationship between epidermal hyperproliferation and skin tumor promotion. In: Carcinogenesis. Cocarcinogenesis and Biolgical Effects of Tumor Promoter. Eds: Hecker E, Fusenig, NE, Kunz, W., Marks, F, Theilman, HW, Raven Press, NY, 331-346. (1982)
73. Fischer, S. M., G. S. Cameron, J. K. Baldwin, D. W. Jasheway, K. E. Patrick & M. A. Belury: The arachidonic acid cascade and multistage carcinogenesis in mouse skin. In: Skin Carcinogenesis: Mechanisms and Human Relevance. Ed: Slaga T J. Alan R. Liss, NY 249-264 (1989)
74. Fürstenberger, G., M. Gross & F. Marks: Eicosanoids and multistage carcinogenesis in NMRI mouse skin: Role of prostaglandins E and F in conversion (first stage of tumor promotion) and promotion (second stage of tumor promotion). Carcinogenesis 10, 91-96 (1989)
75. Fischer, S. M., G. Fürstenberger, F. Marks & T. J. Slaga: Events associated with mouse skin tumor promotion with respect to arachidonic acid metabolism: A comparison between SENCAR and NMRI mice. Cancer Res 47, 3174-3179 (1987)
76.Müller-Decker, K., K. Scholz, F. Marks & G. Fürstenberger: Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Molec Carcinogenesis 12, 31-41 (1995)
77.Rho, O., L. M. Beltran, I. B. Gimenez-Conti & J. DiGiovanni: Altered expression of the epidermal growth factor receptor and transformimg grtowth factor alpha during multistage skin carcinogenesis in SENCAR mice. Molec Carcinogenesis 11, 19-28 (1994)
78.Kudo, T., T. Narisawa & S. Abo: Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 71, 260-264 (1980)
79.Pollard, M. & P. H. Luckert: Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 70, 1103-1105 (1983)
80.Reddy, B. S., J. Nayini, K. Tokumo, J. Rigotty, E. Zang & G. Kellof: Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with DL-alpha-difluoromethy-lornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 50, 2562-2568 (1990)
81.Rao, C. V., K. Tokumo, J. Rigotty, E. Zang, G. Kelloff & B. S. Reddy: Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 51, 4528-4534 (1991)
82.Moorghen, M., P. Ince, K. J. Finney, J. P. Sunter, D. R. Appleton & A. J. Watso: A protective effect of sulindac against chemically-induced primary colonic tumours in mice. J Pathol 156, 341-347 (1988)
83.Pollard, M. & P. H. Luckert: Effect of piroxicam on primary intestinal tumors induced by rats by N-methylnitrosourea. Cancer Lett 25, 117-121 (1984)
84.Reddy, B. S., H. Maruyama & G. Kelloff: Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory durg, during different stages of rat colon tumor development. Cancer Res 47, 5340-5346 (1987)
85.Lombardino, J. G. & E. H. Wiseman: Piroxicam and other anti-inflammatory oxicams. Med Res Rev 2, 127-152 (1982)
86.Pollard, M. & P. H. Luckert: Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64, 1323-1327 (1980)
87.Narisawa, T., M. Sato, M. Tani, T. Kudo, T. Takahashi & A. Goto: Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res 41, 1954-1957 (1981)
88.Boughton-Smith, N. K. & B. J. R. Whitle: Laboratory methods for studying the role of eiosanoids ininflammatory bowel disease. In: Eicosanoids and the Gastrointestinal Tract. MTP Press, Boston 12-45 (1992)
89.Maxwell, W. J., D. Kelleher, J. J. Keating, F. P. Hogan, F. J. Bloomfield, G. S. MacDonald & P. W. N. Keeling: Enhanced secretion of prostaglandin E2 by tissue-fixed macrophages in colonic carcinoma. Digestion 47, 160-166 (1990)
90.Earnest, D. L., L. J. Hixson & D. S. Alberts: Pinoxicam and other cyclooxygenase inhibitors: Potential for cancer prevention. J Cell Biochem 161, 156-166 (1992)
91.Hubbard, W. C., M. C. Alley, T. L. McLemore & M. R. Boyud: Fatty acid cyclooxygenase metabolism of arachidonic acid in human tumor cells. In: Eicosanoids and Other Bioactive Lipids in Cancer and Radiation Injury. Eds: Honn K V, Marnett L J, Nigam S, Walden Jr. T. Norwell: Kluwer Academic Publishers 27-32 (1991)
92.DuBois, R. N., A. Radhika, B. S. Reddy & A. J. Entingh: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterol 110, 1259-1262 (1996)
93.Sano, H., Y. Kawahito, R. L. Wilder, A. Hashiramoto, S. Mukai, K. Asai, S. Kimiora, H. Kato, M. Kondo & T. Hla: Expression of cyclooxygenae-1 and -2 in human colorectal cancer. Cancer Res 55, 3785-3789 (1995)
94.Kargman, S. L., G. P. O'Neill, P. J. Vickers, J. F. Evans, J. A. Mancini & S. Jothy: Expression of prostaglandin G/H synthase-1 and -2 protein. Cancer Res 55, 2556-2559 (1995)
95.Eberhart, C. E., R. J. Coffee, A. Radhika, F. M. Giardiello, S. Ferrenbach & R. N. Dubois. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188 (1994)
96.Pugh, S. & G. A. O. Thomas: Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 35, 675-678 (1994)
97.Moser, A. R., H. C. Pitot & W. F. Dove: A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247, 322-325 (1990)
98.Williams, C. S., C. Luongo, A. Radhika, T. Zhang, L. W. Lamps, L. B. Nanney, R. D. Beauchamp & R. N. DuBois: Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterol 111, 1134-1140 (1996)
99.Boolbol, S. K., A. J. Dannenberg, A. Chadburn, C. Martucci, X-J Gu, J. T. Ramonetti, M. Abreu-Goris, H. L. Newmark, M. L. Lipkin, J. J. DeCoss & M. M. Bertagnolli: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomations polyposis. Cancer Res 56, 2556-2560 (1996)
100.Oshima, M., J. E. Dinchuk, S. L. Kargman, H. Oshima, B. Hancock, E. Kwong, J. M. Trzaskos, J. F. Evans & M. M. Taketo: Suppression of intestinal polyposis in APCd716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87, 803-809 (1996)
101.Waddell, W. R., G. F. Gasner, E. J. Cerise & R. W. Loughry: Sulindac for polyposis of colon. Am J Surg 157, 175-178 (1989)
102.Rigau, J., J. M. Pique, E. Rubio, R. Planas, J. M. Tarrech & J. M. Bordas: Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 115, 952-954 (1991)
103.Labayle, D., D. Fischer, P. Vielh, F. Drouhin, A. Pariente, C. Bories, O. Duhamel, M. Trousset & P. Attali: Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101, 635-639 (1991)
104.Klein, W. A., H. H. Miller, M. Anderson & J. J. DeCosse: The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis. Cancer (Phila) 60, 2863-2868 (1987)
105.Shen, T. Y. & C. A. Winter: Chemical and biological studies on indomethacin, sulindac and their analogs. Adv Drug Res 12, 89-245 (1977)
106.Kune, G. A., S. Kune & L. F. Watson: Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48, 4399-4404 (1988)
107.Rosenberg, L., J. R. Palmer, A. G. Zauber, M. E. Warshauer, P. D. Stolley & S. Shapiro: A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of the large-bowel cancer. J Natl Cancer Inst 83, 355-358 (1991)
108.Thun, M. J., M. M. Namboodiri & C. W. Heath Jr.: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325, 1593-1596 (1991)
109.Greenberg, E. R., J. A. Baron, D. H., Freeman, J. S. Mandel & R. Haile: Reduced risk of large-bowel adenomas among aspirin users. J Natl Cancer Inst 85, 912-916 (1993)
110.Suh, O., C. Mettlin & N. J. Petrelli: Aspirin use, cancer, and polyps of the large bowel. Cancer 72, 1171-1177 (1993)
111.Giovannucci E., E. B. Rimm, M. J. Stampfer, G. A. Colditz, A. Ascherio & W. C. Willett: Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 121, 241-246 (1994)
112.Gann, P. H., J. E. Manson, R. J. Glynn, J., E. Buring & C. H. Hennekens: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85, 1220-1224 (1993)
113.Pollard, M., P. H. Luckert & M. A. Schmidt: The suppressive effect of piroxicam on autochthonous intestinal tumors in rats. Cancer Lett 21, 57-61 (1983)
114.Schreinemachers, D. M. & R. B. Everson: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5, 138-146 (1994)
115.Tan, W. C., O. S. Privett & M. E. Golddyne: Studies of prostaglandins in rat mammary tumors induced by 7,12-dimethylbenz(a)anthracene. Cancer Res 34, 3229-3231 (1974)
116.Abou-El-Ela, S. H., K. W. Prasse, R. L. Farrell, R. W. Carroll, A. E. Wade & O. R. Bunce: Effects of D,L-2-Difluoromethylornithine and indomethacin on mammary tumor promotion in rats fed high n-3 and/or n-6 fat diets. Cancer Res 498, 1434-1440 (1989)
117.Carter, C. A., M. M. Ip & C. Ip: A comparison of the effects of the prostaglandin synthesis inhibitors indomethacin and carprofen on 7-2-dimethylbenz[a]anthracene-induced mammary tumorigenesis in rats fed different amounts of essential fatty acid. Carcinogenesis 10, 1369-1374 (1989)
118.Noguchi, M., T. Taniya, N. Koyasaki, T. Kumaki, I. Miyazaki & Y. Mizukami: Effects of the Prostaglandin synthetase inhibitor indomethacin on tumorigenesis, tumor proliferation, cell kinetics, and receptor contents of 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in Sprague-Dawley rats fed a high- or low-fat diet. Cancer Res 51, 2683-2689 (1991)
119.Bennett, A., A. M. McDonald, J. S. Simpson & I. F. Stamford: Breast cancer, prostaglandins, and bone metastases. Lancet 1, 1218-1220 (1975)
120.Bennett, A., E. M. Charlier, A. M. McDonald, J. S. Simpson, I. F. Stamford & T. Zebro: Prostaglandins and breast cancer. Lancet 2, 624-626 (1977)
121.Karmali, R. A.: Eicosanoids in breast cancer. Eur J Cancer Clin Oncol 23, 5-7 (1987)
122.Schrey, M. P. & K. V. Patel: Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Brit J Cancer 72, 1412-1419 (1995)
123.Rolland, P. H., P. M. Martin, J. Jacquemier, A. M. Rolland & M. Toga: Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst 64, 1061-1070, (1980)
124.Liu, X-H. & D. P. Rose: Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56, 5125-5127 (1996)
125.Watson, D. M., R. W. Kelly & W. R. Miller: Prostaglandins and prognosis in human breast cancer. Br J Cancer 56, 367-370 (1987)
126.Harris, R. E., K. K. Namboodiri & W. B. Farrar: Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 7, 203-205 (1996)
127.Lecomte, M., O. Laneuville, C. Ji, D. L. DeWitt & W. L. Smith: Acetylation of human prostaglandin endoperoxide synthase-2 (cycloxygenase-2) by aspirin. J Biol Chem 269, 13207-13215 (1994)
128.Meade, E. A., W. L. Smith & D. L. DeWitt: Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 268, 6610-6614 (1993)
129.Kulmacz, R. J. & W. E. M. Lands: Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammaory agents. J Biol Chem 260, 12572-12578 (1985)
130.Mitchell, J. A., P. Akarasereenont, C. Thiemermann, R. J. Flower & J. R. Vane: Proc Natl Acad Sci USA 90, 11693-11697 (1994)
131.Rome, L. H. & W. E. M. Lands: Structural requirements for time-dependent inhibition of prostaglandin biosynthesis by anti-inflammatory drugs. Proc Natl Acad Sci USA 72, 4863-4865 (1975)
132.Vane, J. R. & R. M. Botting: New insights into the mode of action of anti-inflammatory drugs. Inflamm Res 44, 1-10 (1995)
133.Masferrer, J. L., B. S. Zweifel, P. T. Manning, S. D. Hauser, K. M. Leahy, W. G. Smith, P. C. Isakson & K. Seibert: Selective inhibition of inducible cyclooxygenase 2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci USA 91, 3228-3232 (1994)
134.Futaki, N., S. Takahashi, M. Yokoyama, I. Arai, S. Higuchi & S. Otoma: NS-392, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenae (COX-2) activity in vitro. Prostaglandins 47, 55-59 (1994)
135.Copeland, R. A., J. M. Williams, J. Giannaras, S. Nurnberg, M. Covington, D. Pinto, S. Pick & J. M. Trzaskos: Mechanisms of selective inhibition of the inducible form of prostaglandin G/H synthase. Proc Natl Acad Sci USA 94, 11202-11206 (1994)
136.Klein, T., R. M. Nüsing, J. Pfeilschifter & V. Ullrich. Selective inhibition of cyclooxygenase 2. Biochem Pharmacol 48, 1605-1610 (1994)
137.Chan, C.-C., S. Boyce, C. Brideau, A-W Ford-Hutchison, R. Gordon, D. Guay, R. G. Hill, C.-S. Li, J. Mancini, M. Penneton, P. Prasit, R. Rasori, D. Reindeau, P. Roy, P. Tagari, P. Vickers, E. Wong & I.W. Rodger: Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: A novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharm Exp Ther 274, 1531-1537 (1995)
138.Langenbach, R., S. G. Morham, H. F. Tiano, C. D. Loftin, G. I. Ghanayem, P. C. Chulada, J. F. Mahler, C. A. Lee, E. H. Goulding, K. D. Kluckman, H. S. Kim & O. Smithies: Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulteration. Cell 83, 483-492 (1995)
139.Morham, S. G., R. Langenbach, C. D. Loftin, H. F. Tiano, N. Vouloumanos, J. C. Jennette, J. F. Mahler, K. D. Kluckman, A. Ledford, C. A. Lee & O. Smithies: Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83, 473-482 (1995)
140.Dinchuk, J. E., B. D. Car, R. J., Focht, J. J. Johnston, B. D. Jafee, M., B. Covington, N. R. Contel, V. M. Eng, R. J. Collins, P. M. Czerniak, S. A. Gorry & J. M. Trzaskos: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature 378, 406-409 (1995)
141.Oliw, E., E. Granstrom & E. Anggard: The prostaglandins and essential fatty acids. In: Prostaglandins and Related Substances. Eds: Pace-Asciak C, Granstrom E. Elsevier Science Publishers, Amsterdam 1-44 (1983)
142.Nolan, R. D., R. M. Danilowicz & T. E. Eling: Role of arachidonic acid metabolism in the mitogenic response of Balb/c 3T3 fibroblasts to epidermal growth factor. Mol Pharmacol 33, 650-656 (1988)
143.Hakeda, Y., S. Harada, T. Matsumoto, K. Tezuka, K. Higashino, H. Kodama, T. Hashimoto-Goto, E. Ogata & M. Kumegawa: Prostaglandin F2a stimulates proliferation of clonal osteopblastic MC3T3-E1 cells by up-regulation of insulin-like growth factor 1 receptors. J Biol Chem 266, 21044-21050 (1991)
144.Honn, K. V., R. S. Bockman & L. J. Marnett: Prostaglandins and cancer: a review of tumor initiation through tumor metastases. Prostagalndins 21, 833-859 (1981)
145.Fürstenberger, G. & F. Marks: Indomethacin inhibition of cell proliferation induced by the phorbol ester TPA is reversed by prostaglandin E2 in mouse epidermis in vivo. Biochem Biophys Res Commun 84, 1103-1108 (1978)
146.Fürstenberger W C & F Marks: Prostaglandins, epidermal hyperplasia and skin tumor promotion. In: Arachidonic Acid Metabolism and Tumor Promotion Eds: Fischer S M, Slaga T J. Martinus Nijhoff Publ., Boston, 49-72 (1985)
147.Fürstenberger, G., M. Gross, J. Schweizer, I. Vogt & F. Marks: Isolation, characterization and in vitro cultivation of subfractions of neonatal mouse keratinocytes: Effects of phorbol esters. Carcinogenesis 7, 1745-1753 (1986)
148.Pentland, A. P. & P. Needleman: Modulation of keratinocyte proliferation in vitro by endogenous prostaglandin synthesis. J Clin Invest 77, 246-251 (1986)
149.Lupulescu, A.: Cytologic and metabolic effects of prostaglandins on rat skin. J Invest Dermatol 68, 138-45 (1977)
150.Verma, A. K., C. L. Ashendel & R. K. Boutwell: Inhibition by prostaglandin synthesis inhibitors of the induction of epidermal ornithine decarboxylase activity, the accumulation of prostaglandins and tumor promotion caused by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 40, 708-715 (1980)
151.Fürstenberger, G, M Gross & F Marks: Involvement of prostaglandins in the process of skin tumor promotion. In: Icosanoids and Cancer. Eds: Thaler-Dao H, Crastes de Paulet A, Paoletti R. Raven Press, NY 91-100 (1984)
152.Sheng, H., J. Shao, S. C. Kirkland, P. Isakson, R., J. Coffey, J. Morrow, R. D. Beauchamp & R. N., DuBois: Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99, 2254-2259 (1997)
153.Qiao, L., V. Kozoni, G. J. Tsioulias, M. I. Koutsos, R. Hanif, S. J. Shiff & B. Rigas: Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochem Biophys Acta 1258, 215-223 (1995)
154.Shiff, S. J., L. Qiao, L.-L. Tsai & B. Rigas: Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 96, 491-503 (1995)
155.Shiff, S. J., M. I. Koustsos, L. Qiao & B. Rigas: Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 222, 179-188 (1996)
156.Tsujii, M., S. Kawano & R. N. DuBois: Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 94, 3336-340 (1997)
157.Craven, P. A., R. Saito & F. R. DeRubertis: Role of local prostaglandin synthesis in the modulation of proliferative activity of rat colonic epithelium. J Clin Invest 72, 1365-1375 (1983)
158.Fischer, S. M., G. D. Mills & T. J. Slaga. Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism. Carcinogenesis 3, 1243-1245 (1982)
159.Tsujii, M. & R. N. DuBois: Alterations in cellular adhesion and apoptsois in epithelial cells overexpressing prostagalndin endoperoxide synthase 2. Cell 83, 493-501 (1995)
160.Hixson, L., D. Alberts, M. Krutzsch, J. Einspahr, K. Brendel, P. H. Gross, N. S. Paranka, M. Baier, S. Emerson, R. Pamukcu & R. Burt: Antiproliferative effect of nonsteroidal anti-inflammatory drugs (NSAIDs) against human colon cancer cells Cancer Epideiol Biomarkers & Prev 3, 433-438 (1994)
161.Piazza, G. A., A. L. Kulchak-Rahm, M. Krutzsch, G. Sperl, N. Shipp-Puranka, P. H. Gross, K. Brendel, R. W. Burt, D. S. Alberts, R. Pamukcu & D. J. Ahnen: Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 55, 3110-3116 (1995)
162.Shiff, S. J., L. Qiao & B. Rigas: Sulindac sulfide, an aspirin-like compound, inhibit cell proliferation, causes cell cycle quiescence, and induces apoptosis in Ht-29 colon adenocarcinoma cells. J Clin Invest 96, 491-503 (1995)
163.Lu, S., W. Xie, T. Reed, W. S. Bradshaw & D. L. Simmons: Nnsteroidal anti-inflammatory drugs cause apoptosis and induce cyclooxygenases in chicken embryo fibroblasts. Proc Natl Acad Sci USA 92, 7961-7965 (1995)
164.Elder, D. J. E., A. Hague, D. J. Hicks & C. Paraskeva: Different growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 56, 2273-2376 (1996)
165.McGill, G. & D. E. Fisher: Apoptosis in tumorigenesis and cancer therapy. Front. Biosci. 2, d353-379, (1997) http://www.bioscience.org/1997/v2/d/fisher/list.htm.
166.Duggan, D. E., H. F. Hooke, E. A. Riskley, T. Y. Shen & C. G. Van Arman: Identification of the biologically active form of sulkindac. J Pharmacol Exp Ther 201, 8-13 (1977)
167.Strong, H. A., N. J. Warner, A. G. Renwick & C. F. George: Sulindac metabolism: the importance of an intact colon. Clin Pharmacol Ther 38, 387-393 (1985)
168.Thompson, H. J., S. Briggs, N. S. Paranka, G. A. Piazza, K. Brendel, P. H. Gross, G. J. Sperl, R. Pamukcu & D. J. Ahnen: Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 87, 1259-1260 (1995)
169.Charalambous, D. & P. E. O'Brien: Inhibition of colon cancer precursors in the rat by sulindac sulphone is not dependent on inhibition of prostaglandin synthesis. J Gastoenterol 11, 307-310 (1996)
170.Piazza, G. A., D. S. Alberts, L. J. Hixson, N. S. Paranka, H. Li, T. Finn, C. Bogert, J. M. Guillen, K. Brendel, P. H. Gross, G. Sperl, J. Ritchie, R. W. Burt, L. Ellsworth, D. J. Ahnen & R. Pamukcu: Sulindac sulfne inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 57, 2909-2915 (1997)
171.Hanif, R., A. Pittas, Y. Feng, M. I. Koutsos, L. Qiao, L. Staiano-Coico, S. I. Shiff & B. Riggs: Effects of non-steroidal anti-inflammatory drugs on proliferation and induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 52, 237-425 (1996)
172.Abramson S. B. & G. Weissmann: The mechanisms of action of antiinflammatory drugs. Arthritis Rheum 32, 1-9 (1989)
173.Eling, T. E., D. C. Thompson, G. L. Foureman, J. F. Curtis & M. F. Hughes: Prostaglandin H synthase and xenobiotic oxidation. Ann Rev Pharmacol Toxicol 30, 1-45 (1990)
174.Smith, B. J., J. F. Curtis & T. E. Eling:. Bioactivation of xenobiotics by prostaglandin H synthetase. Chem Biol Interact 79, 245-264 (1991)
175.Robertson, I. G. C., K. Sivarajah, T. E. Eling & E. Zeiger: Activation of some aromatic amines to mutagenic products by prostaglandin endoperoxide synthetase. Cancer Res 43, 476-480 (1983)
176.Zenser, T. V., S. M. Cohen, M. B. Mattamal, R. W. Wise, N. S. Rapp & B. B. Davis: Prostaglandin hydroperoxidase-catalyzed activation of certain N-substituted aryl renal and bladder carcinogens. Environ Health Persp 49, 33-41 (1983)
177.Murasaki, G., T. V. Zenser, B. B. Davia & S. M. Cohen: Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazoyl] formamide-induced bladder carcinogenesis. Carcinogenesis 5, 53-55 (1984)
178.Wild, D. & G. H. Degan: Prostaglandin H synthetase-dependent mutagenic acitivty of heterocyclic aromatic amines of the IQ type. Carcinogenesis 8, 541-545 (1987)
179.Marnett, L. J.: Peroxyl-free radicals: Potential mediators of tumor initiation and promotion. Carcinogenesis 8, 1365-1373 (1987)
180.Benamira, M., K. Johnson, A. Chaudhary, K. Bruner, C. Tibbetts & L. J. Marnett: Induction of mutations by replication of malondialdehyde-modified M13 DNA in Escherichia coli: determination of the extent of DNA modification, genetic requirements for mutagenesis, and types of mutations induced. Carcinogenesis 16, 93-99 (1995)
181.Plescia, O. & S. Racis: Prostaglandins as physiological immunoregulators. Prog Allergy 44, 153-171 (1988)
182.Baich, C. M., P. A. Doghert, G. A. Cloud & A. B. Tilden:. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer cancer patients. Surgery 95, 71-77 (1984)
183.Han, T. & H. Takita: Indomethacin-mediated enhancement of lymphocyte response to mitogens in healthy subjects and lung cancer patients. Cancer 46, 2416-2420 (1980)
184.Taffert, S. M. & S. W. Russell: Macrophage-mediated tumor cell killing: Regulation of expression of cytolytic activity by prostaglandin E. J Immunol 126, 424-427 (1981)
185.Brunda, M. J., R. B. Heberman & H. T. Holden: Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 124, 2682-2687 (1980)
186.Goodwin, J. S.: Immunological effects of nonsteroidal anti-inflammatory drugs. Am J Med 77, 7-15 (1984)
187.Cantrow, W. D., H. T. Cheuing & G. Sundharadas: Effects of prostaglandins on the spreading, adhesion and migration of mouse peritoneal macrophages. Prostaglandins 63, 39-46 (1978)
188.Goodwin, J. S., A. D. Bankhurst & R. P. Messner: Suppression of human T-cell mitogenesis by prostaglandin; existence of a prostaglandin-producing suppressor cell. J Exp Med 146, 1719-1734 (1977)
189.Bockman, R. S.: PGE inhibition of T-lymphocyte colony formation. J Clin Invest 64, 812-821 (1972)
190.Strausser, H. R. & J. L. Humes: Prostaglandin synthesis inhibition: effect on bone changes and sarcoma tumor induction in BALB/c mice. Int J Cancer 15, 724-730 (1975)
192.Lynch, N. R. & J.-C. Salomon: Tumor growth inhibition and potentiation of immunotherapy by indomethacin in mice. J Natl Cancer Inst 62, 117-121 (1979)
193.Young, M. R., M. E. Young & K. Kim: Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinomas by prostaglandin E2. Cancer Res 48, 6826-6831 (1988)
194.Young, M. R., G. P. Duffie,Y. Lozano, M. E. Young & M. A. Wright: Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic Lewis lung carcinoma variants. Cancer Res 50, 2973-2978 (1990)